Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Local delivery of OX40L, CD80, and CD86 mRNA kindles global anti-cancer immunity.

Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, Wender PA, Levy R.

Cancer Res. 2019 Jan 28. pii: canres.2867.2018. doi: 10.1158/0008-5472.CAN-18-2867. [Epub ahead of print]


mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.

Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):E9153-E9161. doi: 10.1073/pnas.1810002115. Epub 2018 Sep 10.


Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity.

Fauskanger M, Haabeth OAW, Skjeldal FM, Bogen B, Tveita AA.

Front Immunol. 2018 Jul 23;9:1684. doi: 10.3389/fimmu.2018.01684. eCollection 2018.


Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters.

McKinlay CJ, Benner NL, Haabeth OA, Waymouth RM, Wender PA.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5859-E5866. doi: 10.1073/pnas.1805358115. Epub 2018 Jun 11.


CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs.

Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA.

Cancer Res. 2018 Aug 15;78(16):4573-4585. doi: 10.1158/0008-5472.CAN-17-2426. Epub 2018 May 11.


iNOS- and NOX1-dependent ROS production maintains bacterial homeostasis in the ileum of mice.

Matziouridou C, Rocha SDC, Haabeth OA, Rudi K, Carlsen H, Kielland A.

Mucosal Immunol. 2018 May;11(3):774-784. doi: 10.1038/mi.2017.106. Epub 2017 Dec 6.


Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA.

Nature. 2017 Mar 30;543(7647):723-727. doi: 10.1038/nature21433. Epub 2017 Mar 22.


Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response.

Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, Bogen B, Corthay A.

Cancer Res. 2016 Dec 1;76(23):6864-6876. Epub 2016 Sep 12.


Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.

Tveita A, Fauskanger M, Bogen B, Haabeth OA.

Oncotarget. 2016 Oct 11;7(41):67175-67182. doi: 10.18632/oncotarget.11946.


Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.

Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A.

Oncoimmunology. 2015 Jul 25;5(1):e1039763. eCollection 2016.


Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.

Haabeth OA, Tveita A, Fauskanger M, Hennig K, Hofgaard PO, Bogen B.

Leukemia. 2016 May;30(5):1216-20. doi: 10.1038/leu.2015.278. Epub 2015 Oct 9. No abstract available.


Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.

Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B.

Cancer Res. 2015 Aug 15;75(16):3268-78. doi: 10.1158/0008-5472.CAN-14-3640. Epub 2015 Jun 2.


Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen.

Tveita AA, Haabeth OA, Bogen B.

Oncoimmunology. 2014 Dec 13;3(9):e954953. eCollection 2014 Oct.


Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells.

Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B.

Eur J Immunol. 2014 Sep;44(9):2625-37. doi: 10.1002/eji.201444659. Epub 2014 Jun 20.


How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B.

Front Immunol. 2014 Apr 15;5:174. doi: 10.3389/fimmu.2014.00174. eCollection 2014. Review.


Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells.

Jacobsen J, Haabeth OA, Tveita AA, Schjetne KW, Munthe LA, Bogen B.

J Immunol. 2014 May 1;192(9):4174-83. doi: 10.4049/jimmunol.1302359. Epub 2014 Apr 4.


Molecular profiling of tumor-specific TH1 cells activated in vivo.

Lorvik KB, Haabeth OA, Clancy T, Bogen B, Corthay A.

Oncoimmunology. 2013 May 1;2(5):e24383.


A model for cancer-suppressive inflammation.

Haabeth OA, Bogen B, Corthay A.

Oncoimmunology. 2012 Oct 1;1(7):1146-1155.


Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.

Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A.

Nat Commun. 2011;2:240. doi: 10.1038/ncomms1239.

Supplemental Content

Loading ...
Support Center